CorAlert is developing an accurate, easy-to-use, noninvasive detection and monitoring device for diagnosing heart failure (HF) in real time.
The market seeks a low-cost, noninvasive solution for early detection and monitoring of patients suffering from HF.
Left Ventricular End-Diastolic Pressure (LVEDP), the pressure in the left ventricle after it has filled with blood and before it contracts, is an accepted measure to identify patients suffering from HF. In nearly all people with HF, LVEDP is elevated. Unfortunately, measuring LVEDP involves an invasive procedure that is rarely performed today.
CorAlert is developing an accurate, easy-to-use, noninvasive device for early detection and monitoring of HF in real time. CorAlert’s device accurately estimates LVEDP based on analyzing central aortic pressure and measuring heartbeats. The system consists of the CorAlert smart pump placed on the upper arm, a sensor placed on the chest, and CorAlert’s proprietary software for accurate estimates and analysis of LVEDP.
The Company’s noninvasive method provides a full hemodynamic profile based on three critical measurements:
CorAlert represents a new approach in the practice of cardiology that will significantly improve patient healthcare and reduce hospital costs. Its unique solution has been validated in more than 50 patients at Johns Hopkins Hospital, followed by a study at Kaplan and Ziv Medical Centers in Israel.
Founded: September 2016
Stage: Technology development
Investor: The Trendlines Group
Heart failure (HF) occurs as the heart muscle weakens. As a result, the heart struggles to meet the body’s needs. This condition manifests itself in shortness of breath, fatigue, and sudden weight gain. In its early stages, HF often goes undetected. As HF progresses, however, it may cause pulmonary edema, hospitalization, or death. HF affects 26 million adults worldwide, with more than 5.7 million in the United States. Up to 42% of patients admitted to hospitals with HF die within five years.
Both the mortality rate and high cost of treating HF are due to the difficulty in assessing the patient’s condition in real time, which may result in misdiagnosis.
CEO Amir Marmor is interviewed on ILTV.
Amir Marmor, CEO
Wireless, wearable vital sign monitoring system
Cryotherapy for superficial bladder cancer
Endoscopic ultrasound fine needle biopsy
Portable, automatic system for peritoneal dialysis
Device for treating ischemic stroke
Anastomotic closure device for laparoscopic bowel resection